Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a …

WS Redfern, L Carlsson, AS Davis… - Cardiovascular …, 2003 - academic.oup.com
Objective: To attempt to determine the relative value of preclinical cardiac electrophysiology
data (in vitro and in vivo) for predicting risk of torsade de pointes (TdP) in clinical use …

H1‐antihistamines: inverse agonism, anti‐inflammatory actions and cardiac effects

R Leurs, MK Church… - Clinical & Experimental …, 2002 - Wiley Online Library
This review addresses novel concepts of histamine H1‐receptor function and attempts to
relate them to the anti‐inflammatory effects of H1‐antihistamines. Furthermore, the …

Five colour variants of bright luminescent protein for real-time multicolour bioimaging

K Suzuki, T Kimura, H Shinoda, G Bai… - Nature …, 2016 - nature.com
Luminescence imaging has gained attention as a promising bio-imaging modality in
situations where fluorescence imaging cannot be applied. However, wider application to …

Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development

S Whitebread, J Hamon, D Bojanic, L Urban - Drug discovery today, 2005 - Elsevier
Broad-scale in vitro pharmacology profiling of new chemical entities during early phases of
drug discovery has recently become an essential tool to predict clinical adverse effects …

Toward a Pharmacophore for Drugs Inducing the Long QT Syndrome:  Insights from a CoMFA Study of HERG K+ Channel Blockers

A Cavalli, E Poluzzi, F De Ponti… - Journal of medicinal …, 2002 - ACS Publications
In this paper, we present a pharmacophore for QT-prolonging drugs, along with a 3D QSAR
(CoMFA) study for a series of very structurally variegate HERG K+ channel blockers. The …

QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development

M Recanatini, E Poluzzi, M Masetti… - Medicinal research …, 2005 - Wiley Online Library
Prolongation of the QT interval of the electrocardiogram is a typical effect of Class III
antiarrhythmic drugs, achieved through blockade of potassium channels. In the past decade …

Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview

F De Ponti, E Poluzzi, A Cavalli, M Recanatini… - Drug safety, 2002 - Springer
The long and growing list of non-antiarrhythmic drugs associated with prolongation of the QT
interval of the electrocardiogram has generated concern not only for regulatory interventions …

Chronic urticaria: aetiology, management and current and future treatment options

MMA Kozel, RA Sabroe - Drugs, 2004 - Springer
Chronic urticaria is a common condition that can be very disabling when severe. A cause for
chronic idiopathic urticaria (CIU) is only infrequently identified. Potential causes include …

Psychotropic drugs, cardiac arrhythmia, and sudden death

HJ Witchel, JC Hancox, DJ Nutt - Journal of clinical …, 2003 - journals.lww.com
A variety of drugs targeted towards the central nervous system are associated with cardiac
side effects, some of which are linked with reports of arrhythmia and sudden death. Some …

QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience

F De Ponti, E Poluzzi, N Montanaro - European journal of clinical …, 2000 - Springer
Background: Evidence has accrued that several non-cardiac drugs may prolong cardiac
repolarisation (hence, the QT interval of the surface electrocardiogram) to such a degree that …